FLiRT COVID variants: What are they and are they more contagious?
Adds details on KP.3 variant, U.S. vaccines
By Michael Erman
NEW YORK, July 9 (Reuters) -The so-called FLiRT variants of SARS-CoV-2 coronavirus that cause COVID-19 have been the dominant forms of the virus circulating this year globally, according to the World Health Organization
FLiRT is an acronym for the locations of the mutations the variants share on the virus' spike protein. One of them, called KP.3, has become the most commonly circulating variant in the United States over the past month, according to the U.S. Centers for Disease Control and Prevention.
Here is what you need to know about FLiRT.
HOW ARE FLIRT VARIANTS DIFFERENT FROM PREVIOUS VARIANTS?
The FLiRT variants, which also include KP.3's "parental" lineage JN.1, have three key mutations on their spike protein that could help them evade antibodies, according to Johns Hopkins University.
ARE FLIRT VARIANTS MORE CONTAGIOUS OR LIKELY TO CAUSE MORE SEVERE ILLNESS?
Dr. Aaron Glatt, chief of infectious diseases at Mount Sinai South Nassau Hospital in Oceanside, New York, and a spokesperson for the Infectious Diseases Society of America said in May that he had not seen evidence of an uptick in disease or hospitalizations, based on the data he tracks and experience with his own patients.
"There have been some significant changes in the variants, but I think in recent times it's not been as important, probably because of the immunity many, many people already have" from prior illness and vaccination.
CDC data suggests that COVID-related hospitalizations have risen slightly since April and the number of patients in emergency departments who have tested positive for COVID has increased since May, in line with trends a year ago.
DO CURRENT VACCINES WORK AGAINST THE FLIRT VARIANTS?
The current vaccines should still have some benefit against the new variants, Glatt said.
Since 2022, health regulators have asked vaccine makers to design new versions of the COVID-19 vaccines to better target circulating variants.
Europe's regulator has said vaccine makers should target the JN.1 variant. U.S. regulators asked for the vaccines to target variants within the JN.1 lineage, but said the preferred strain to target would be the KP.2 strain, which was dominant in June.
Reporting by Michael Erman; editing by Caroline Humer and Bill Berkrot
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
